When does GenSight report earnings and why does it matter for SIGHT.PA stock?

GenSight reports on **20 Mar 2026**. The update matters because clinical readouts and cash guidance can cause large intraday moves in SIGHT.PA stock, given limited liquidity and the firm's clinical-stage status.

What is Meyka AI's forecast and how does it compare to today's price for SIGHT.PA stock?

Meyka AI's forecast model projects **EUR 0.0137** for one year. Compared with today's **EUR 0.0839**, that implies about **-83.65%** downside. Forecasts are model-based projections and not guarantees.

What are the main risks for investors in SIGHT.PA stock?

Primary risks include clinical trial setbacks, tight liquidity (current ratio **0.11**), low average daily volume, and limited revenue. A negative trial outcome can sharply lower valuation.

Which catalysts could lift SIGHT.PA stock after the earnings release?

Positive clinical updates for LUMEVOQ or GS030, clearer cash runway, new partnerships, or pricing of a financing round could lift SIGHT.PA stock by reducing execution risk and improving liquidity.

EU Stocks

SIGHT.PA GenSight Biologics EURONEXT 16 Mar 2026 earnings: catalysts to watch

ByHuzaifa Zahoor March 16, 2026March 16, 2026

We open intraday on SIGHT.PA stock at EUR 0.0839 ahead of GenSight Biologics’ scheduled earnings announcement on 20 Mar 2026. Traders are watching clinical updates and cash runway guidance. Volume today is 686,586 shares vs an average of 1,875,535. This earnings spotlight focuses on catalysts that can move the stock in the short term.